A detailed history of State Of New Jersey Common Pension Fund D transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, State Of New Jersey Common Pension Fund D holds 82,752 shares of TGTX stock, worth $2.44 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
82,752
Previous 113,683 27.21%
Holding current value
$2.44 Million
Previous $2.02 Million 4.3%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$17.21 - $25.28 $532,322 - $781,935
-30,931 Reduced 27.21%
82,752 $1.94 Million
Q2 2024

Aug 07, 2024

BUY
$13.32 - $19.19 $1.51 Million - $2.18 Million
113,683 New
113,683 $2.02 Million
Q2 2023

Aug 02, 2023

SELL
$15.48 - $35.0 $707,466 - $1.6 Million
-45,702 Reduced 33.27%
91,665 $2.28 Million
Q1 2023

Apr 26, 2023

BUY
$10.23 - $19.34 $1.41 Million - $2.66 Million
137,367 New
137,367 $2.07 Million
Q1 2022

May 03, 2022

SELL
$7.81 - $20.45 $898,618 - $2.35 Million
-115,060 Closed
0 $0
Q4 2021

Jan 31, 2022

SELL
$15.2 - $35.51 $88,509 - $206,774
-5,823 Reduced 4.82%
115,060 $2.19 Million
Q3 2021

Oct 27, 2021

BUY
$21.78 - $40.45 $976,920 - $1.81 Million
44,854 Added 59.0%
120,883 $4.02 Million
Q2 2021

Jul 23, 2021

BUY
$32.5 - $48.96 $358,247 - $539,686
11,023 Added 16.96%
76,029 $2.95 Million
Q1 2021

Apr 27, 2021

SELL
$41.61 - $54.3 $313,864 - $409,584
-7,543 Reduced 10.4%
65,006 $3.13 Million
Q4 2020

Feb 03, 2021

SELL
$25.27 - $54.9 $513,612 - $1.12 Million
-20,325 Reduced 21.88%
72,549 $3.77 Million
Q3 2020

Oct 27, 2020

SELL
$18.49 - $27.24 $127,728 - $188,173
-6,908 Reduced 6.92%
92,874 $2.49 Million
Q2 2020

Aug 04, 2020

BUY
$8.9 - $21.84 $888,059 - $2.18 Million
99,782 New
99,782 $1.94 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track State Of New Jersey Common Pension Fund D Portfolio

Follow State Of New Jersey Common Pension Fund D and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of New Jersey Common Pension Fund D, based on Form 13F filings with the SEC.

News

Stay updated on State Of New Jersey Common Pension Fund D with notifications on news.